AEHR
Aehr Test Systems
97.40$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -4.1% | +0.4% | +25.9% | +14.0% | -2.5% | +2.3% | +2.0% | -3.0% | +3.2% | +5.6% | +57.1% | |
| – | -4.6% | +0.6% | +6.0% | -5.0% | -4.7% | +3.6% | -3.2% | -5.3% | +4.9% | +8.7% | +92.3% | |
| – | -0.9% | -5.8% | +3.3% | -23.0% | -12.6% | -8.9% | -16.2% | -10.0% | +35.8% | +19.7% | +215.2% | |
| – | -0.9% | -5.8% | +3.3% | -23.0% | -12.6% | -8.9% | -16.2% | -10.0% | +35.8% | +19.7% | +215.2% | |
| – | -49.7% | -12.2% | +72.0% | -14.4% | -12.0% | +59.2% | +48.4% | -26.6% | -21.2% | +14.8% | +48.0% | |
| – | +7.2% | +12.6% | -1.6% | +14.7% | +1.9% | -3.3% | -0.8% | -0.4% | +2.1% | -3.7% | +0.5% | |
| – | – | – | – | – | +5.3% | +23.5% | +45.3% | -0.8% | -0.9% | +0.6% | – | |
| – | – | – | – | – | +3.8% | +0.0% | -0.2% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | – | – | – | – | -2.9% | -3.2% | -3.3% | -3.2% | -2.8% | -2.9% | -3.0% | |
| – | -44.6% | +7.7% | +8.1% | +43.3% | -18.3% | +12.0% | +19.8% | -15.4% | -17.2% | +1.6% | +48.9% | |
| – | -58.7% | +15.3% | +14.5% | +46.7% | -24.0% | +37.1% | -2.7% | -23.8% | -30.3% | +5.3% | +104.2% | |
| – | +44.4% | +7.8% | +8.6% | +77.8% | +3.7% | +36.7% | -22.5% | -0.4% | -35.4% | +3.6% | +3.3% | |
| – | -49.8% | +19.0% | +7.1% | +4.5% | -12.9% | +43.4% | -3.3% | -49.8% | +5.0% | -40.7% | +221.2% | |
| – | +8.7% | -0.8% | +29.0% | +9.8% | +0.6% | +0.8% | -1.1% | -0.4% | +6.8% | +6.1% | +58.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.5% | -3.0% | +2.1% | +0.6% | +0.1% | +0.2% | +0.3% | +0.3% | +0.4% | +2.1% | -0.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.